Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trialArticle Published on 2022-11-082022-11-16 Journal: Trials [Category] SARS, 변종, [키워드] adaptive anti-COVID-19 IVIG antivirals clinical evidence clinical trial collected convalescent convalescent plasma COVID-19 cumulative death Efficacy eligibility criteria evaluate Health hyperimmune immunization immunomodulators intravenous Intravenous immunoglobulin low dose monoclonal antibodies Neutralizing non-specific novel Novel coronavirus outcome Passive passive immunization Patient phase Pneumonia polyclonal polyclonal antibodies Pooled convalescent plasma Potential treatment Randomized Randomized controlled trial receive Recovered COVID-19 patients reported SARS CoV-2 SARS CoV-2. SARS-CoV-2 sealed Secondary outcomes severe COVID-19 severe COVID-19 patient severe COVID-19 patients Standard of care Steroids Study protocol therapeutic option therapy treat Treatment Trial variant variants of concern virus virus particles World Health Organization [DOI] 10.1186/s13063-022-06860-2 PMC 바로가기
Mid-term pulmonary sequelae after hospitalisation for COVID-19: The French SISCOVID cohortResearch article Published on 2022-11-012022-10-05 Journal: Respiratory medicine and research [Category] 임상, [키워드] age Chest computed tomography clinical examination Clinical features Cohort complications consequence COVID-19 CT-scan described diffusing discharge Dyspnoea evaluated Follow-up French functional hospital discharge hospitalisation hospitalised ICU impairment Improved independent risk factor intensive care Invasive mechanical ventilation lung lung capacity Lung function mMRC multicentre nasal non-invasive ventilation observational study outcome Pathogenesis Patient Patient discharge Pneumonia Pulmonary function tests radiological Result sequelae severe COVID-19 significantly more therapeutic option ventilatory [DOI] 10.1016/j.resmer.2022.100933 [Article Type] Research article
COVID-19 and Gut InjuryArticle Published on 2022-10-202022-11-15 Journal: Nutrients [Category] COVID19(2023년), SARS, 진단, [키워드] ACE2 acute respiratory syndrome angiotensin-converting enzyme 2 bind change children coronavirus COVID-19 COVID-19 infection COVID-19 patient COVID-19 patients death develop disorder females GI Tract Gut high risk host cell IBD increased risk Inflammatory Inflammatory bowel disease inflammatory cell inhibitor Injury mechanism microbiota monoclonal antibody pandemic Pathologies Patient probiotics. receptor recruitment reduce Respiratory system SARS-CoV-2 secreted cytokine severe COVID-19 susceptible Symptom the disease the patient therapeutic option Viral load [DOI] 10.3390/nu14204409 PMC 바로가기
Endoplasmic reticulum secretory pathway: Potential target against SARS-CoV-2Article Published on 2022-10-152022-11-15 Journal: Virus research [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] accelerate acute respiratory syndrome approach approved benefit caused cell membrane Clinical use coronavirus Coronavirus disease 2019 COVID-19 death demonstrated dependent on drug effort Endoplasmic reticulum ERS pathway Extensive feasibility globe inhibitor New overcome pathway pharmacological Potential Protein protein translation regulatory agencies Replication resulting SARS-CoV-2 SARS-COV-2 infection secretory pathway shown suppress targeting the SARS-CoV-2 therapeutic option unfolded protein response Unfolded protein response. virion [DOI] 10.1016/j.virusres.2022.198897 PMC 바로가기
Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of ConcernArticle Published on 2022-10-142022-11-15 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Ability ACE2 binding antibody Antibody titer Antigen binding domain binding epitope characterized concern coronavirus 2 coronavirus disease COVID-19 COVID-19 neutralizing antibody Delta domains effective high affinity high stability highlight Infection introduced lung cell Neutralizing neutralizing antibody New omicron pathogen plasma Protein RBD respiratory SARS-CoV-2 SARS-CoV-2 receptor SARS-CoV-2 variant SARS-CoV-2 variants single-domain antibody Spike protein spike protein. suggested therapeutic option unique variable variant VNAR therapy was tested was used [DOI] 10.3390/ijms232012267 PMC 바로가기
Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infectionArticle Published on 2022-10-102022-11-15 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 비임상, 진단, [키워드] acute respiratory syndrome animal model anti-SARS-CoV-2 baseline Body weight loss caused China controls convalescent plasma coronavirus COVID-19 COVID-19 vaccines deaths Efficacy evaluated faster hamster hamsters Hospitalization Human Immunoglobulin intravenous Lung inflammation Lung pathology Lungs mice monoclonal antibody mouse model ongoing trial PBS plasma reduced SARS-CoV-2 SARS-COV-2 infection significantly Spread Support therapeutic option treated Treatment Viral load virus was reduced worldwide pandemic [DOI] 10.1038/s41598-022-21223-2 PMC 바로가기
Transchromosomic bovines-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1, and influenza A virusSARS-CoV-2, MERS-CoV, 에볼라, 지카, HIV-1 및 인플루엔자 A 바이러스에 특히 중점을 두고 중요한 신흥 바이러스 병원체에 대응하는 강력한 생물 치료제로서의 형질전환 소 유래 광범위 중화 항체Review Published on 2022-10-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus adjuvant adjuvants Alpha animals antibody antibody-based therapies Antiviral approach approved assist Beta Biotherapeutics blocked bovine bovine-derived biotherapeutics Clinical studies colostrum convalescent coronavirus creating Delta disease Donor E484K Ebola effective Efficiency emerging viruses Epsilon Gamma highlight HIV-1 Human Human immunodeficiency virus human immunodeficiency virus type 1 human infection human infections hyperimmunization immune immunoreactivity Immunotherapy Influenza influenza A influenza A virus Iota K417N L452R Lambda MERS MERS-CoV Middle East Middle East respiratory syndrome Coronavirus mutations N501Y neutralization neutralized Neutralizing Neutralizing activity neutralizing antibody omicron Omicron variants outbreak P681R Pandemics platform polyclonal antibodies polyclonal antibody produced Protective respiratory respiratory syndrome coronavirus robust Safe SARS-CoV-2 serum severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown T478K therapeutic option transchromosomic bovines. Vaccine variant variants variants of concern variants of interest Viral viral infection viral infections viral pathogen VOCs VOIs Zika [DOI] 10.1002/jmv.27907 PMC 바로가기 [Article Type] Review
Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccineReview article Published on 2022-10-012022-10-05 Journal: International immunopharmacology [Category] COVID19(2023년), SARS, 변종, 임상, 치료제, [키워드] acute respiratory syndrome affected antiviral agent approach approved caused Cell Cell based therapy characterized coronavirus coronavirus 2 Coronavirus disease 2019 Corticosteroids COVID-19 drug evaluated Gene therapy high risk highly pathogenic immune Immunotherapy in vitro in vivo Inflammatory Medical conditions modulating outcomes Oxygen therapy Patient Population SARS-CoV-2 syndrome targeted therapy therapeutic option therapy thrombosis Treatment Vaccine variety Vascular injury virus [DOI] 10.1016/j.intimp.2022.109161 [Article Type] Review article
Targeting thromboinflammation in COVID-19 – A narrative review of the potential of C1 inhibitor to prevent disease progressionReview Published on 2022-10-012022-10-05 Journal: Molecular immunology [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, 치료제, [키워드] Activation addition Anti-inflammatory anticoagulation Antiviral Asymptomatic carrier C1 inhibitor cascade cascades caused Clinical practice complement complement system Complication Contact contact activation system Coronavirus disease 2019 COVID-19 Critically ill patient death disease driver drug Endothelial cell Evidence Inflammatory inhibitor introduced kallikrein-kinin Kallikrein-kinin system monoclonal antibodies multisystemic myocardial injury pandemic potential benefit prevent disease progression randomized study randomized trials SARS-CoV-2 severe COVID-19 syndrome targeting the disease therapeutic option Thromboembolic events Thromboinflammation Treatment Trial [DOI] 10.1016/j.molimm.2022.08.008 [Article Type] Review
Potential of Azadirachta indica as a Capping Agent for Antiviral Nanoparticles against SARS-CoV-2Article Published on 2022-09-152022-11-15 Journal: BioMed Research International [Category] SARS, 치료제, [키워드] agent anti-SARS-CoV-2 Antiviral antiviral property antivirals approved article attribute Azadirachta indica capping carried caused China coronavirus COVID-19 database disease effective genetic mutations global pandemic highlight investigation MOST nanoparticle new strain pandemic Pneumonia Potential reported retrieved SARS-CoV-2 screened systematic review the SARS-CoV-2 therapeutic option vaccine candidate Web of Science [DOI] 10.1155/2022/5714035 PMC 바로가기